MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Tata Medical Center
Calcuta, IndiaPublicaciones en colaboración con investigadores/as de Tata Medical Center (3)
2022
-
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)
Breast Cancer Research and Treatment
-
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
Breast Cancer Research and Treatment, Vol. 193, Núm. 1, pp. 95-103
2021
-
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
Breast Cancer Research and Treatment, Vol. 189, Núm. 3, pp. 689-699